Bistable mesomorphism and supramolecular stereomutation in chiral liquid crystal azopolymers
作者:Jesús del Barrio、Rosa M. Tejedor、Luiz S. Chinelatto、Carlos Sánchez、Milagros Piñol、Luis Oriol
DOI:10.1039/b901384a
日期:——
A series of side-chain liquid crystal polymers based on an azobenzene mesogenic unit bearing a terminal chiral chain has been synthesized. The thermal and mesomorphic properties of the homo- and copolymers have been investigated by polarizing optical microscopy, DSC and X-ray diffraction. Polymers having a chiral methylheptyloxy terminal chain (P8S and P8R) exhibit surprising mesomorphic behavior, which depends on the thermal history of the sample. The influence of the molecular chirality and thermal history on the supramolecular organization of the chromophores have also been studied. Supramolecular chiral aggregation of the azobenzenes seems to be responsible for the observed chiroptical properties of these materials, both in solution and solid state (polymeric films), with the handedness controlled by the molecular chirality. Stereomutation of the chiral supramolecular organization is detected when polymeric films of P8S and P8R experience a different thermal history.
我们合成了一系列基于带有末端手性链的偶氮苯介原单元的侧链液晶聚合物。通过偏振光学显微镜、DSC 和 X 射线衍射研究了均聚物和共聚物的热性质和介形性质。具有手性甲基庚氧基末端链(P8S 和 P8R)的聚合物表现出令人惊讶的介形态行为,这种行为取决于样品的热历史。此外,还研究了分子手性和热历史对发色团超分子结构的影响。偶氮苯的超分子手性聚集似乎是这些材料在溶液和固态(聚合物薄膜)中观察到的手性特性的原因,其手性由分子手性控制。当 P8S 和 P8R 的聚合物薄膜经历不同的热历史时,可以检测到手性超分子结构的立体变异。
[EN] POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR<br/>[FR] MODULATEURS ALLOSTERIQUES POSITIFS DE RECEPTEUR NICOTINIQUE DE L'ACETYLCHOLINE
申请人:UPJOHN CO
公开号:WO2003093250A2
公开(公告)日:2003-11-13
The invention provides compounds of Formula I: (1) these compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which α7 nAChR is known to be involved.
Positive allosteric modulators of the nicotinic acetylcholine receptor
申请人:——
公开号:US20030236287A1
公开(公告)日:2003-12-25
The invention provides compounds of Formula I:
1
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals used to treat diseases or conditions in which &agr;7 nAChR is known to be involved.
tail length modification and degree of polymerization (DP) variation. The amorphous-to-LC phase transition and biphasic LC interconversion allow the transcription of three stacking modes, thereby controlling the dynamic reversal of supramolecularchirality.